CSPC PHARMA (01093): SYS 6077 Injection Receives Clinical Trial Approval in China

CSPC PHARMA (01093) announced that the SYS 6077 Injection developed by the group has received a drug clinical trial approval notice issued by China's National Medical Products Administration, allowing clinical trials to be conducted in China. The approved clinical indication for this trial is advanced malignant tumors. This product is a universal off-the-shelf tumor therapeutic messenger RNA (mRNA) vaccine developed based on the group's nano-delivery technology platform. By encoding multiple tumor neoantigens, it induces antigen-specific T-cell immune responses, thereby enhancing the body's ability to recognize and attack tumor cells. Preclinical studies have shown that this product can induce antigen-specific T-cell immune responses against multiple tumor antigens and has demonstrated antitumor activity in multiple preclinical tumor models. Based on these research results, the group will initiate clinical studies of this product to further evaluate its safety, immunogenicity, and preliminary antitumor activity in patients with malignant tumors. The approval of clinical trials for this product marks an important step for the group in mRNA technology and tumor immunity, and it is expected to provide a new treatment option for patients with malignant tumors in the future.